Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingPremera Mammography AI Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera Blue Cross of WashingtonPolicy N/A

    Mammography-Based AI Breast Cancer Risk Prediction

    Customize your policy alerts

    Sign up for all premerabluecrossofwashington policy alerts

    Know when premerabluecrossofwashington releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs mammography-based artificial intelligence software that estimates an individual's 5-year breast cancer risk from bilateral screening mammography. The service is considered investigational because evidence is insufficient to demonstrate effectiveness.

    Policy Summary
    PayerPremera Blue Cross of Washington
    PolicyMammography-Based AI Breast Cancer Risk Prediction
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateFebruary 5, 2027
    Next Review DateN/A
    Key ActionDocument that the input consists of directly acquired bilateral 2D screening mammograms from a validated platform and format.
    SourceLink
    POLICY UPDATE CHANGES

    A new policy was established stating that mammography-based AI risk prediction software used with bilateral screening mammography to estimate 5-year breast cancer risk is investigational.

    InvestigationalCoverage classification
    5 yearsRisk prediction horizon
    BilateralScreening context
    NoneClinical outcome evidence

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Investigational Status and Evidence Requirements

    Mammography-based AI risk prediction

    The service is considered investigational.

    Investigational mammography-based AI risk prediction: Mammography-based AI risk prediction software is used for an individual undergoing bilateral screening mammography to estimate 5-year risk of developing or being diagnosed with breast cancer, without known breast cancer at presentation.

    The policy states that this use is investigational because there is insufficient evidence to show effectiveness.

    Clairity Allix5 imaging acquisition

    For clinical risk prediction with Clairity Allix5, all validated acquisition requirements must be met.

    Validated imaging acquisition: Input images are directly acquired bilateral 2D screening mammograms obtained from Hologic Selenia Dimensions or Lorad Selenia mammography systems.

    Synthetic 2D images, digital breast tomosynthesis-derived 2D images, and images from other manufacturers are outside the validated acquisition profile and should not be used as input for clinical risk prediction with Allix5.

    Insufficient evidence for improved net health outcome

    The evidence review concludes that the evidence is insufficient to determine improvement in net health outcomes.

    Evidence conclusion: The evidence is insufficient to determine that mammography-based AI risk prediction software improves the net health outcome.

    There is no direct evidence that use of Allix5 or Mirai improves health outcomes, and indirect evidence is insufficient to establish clinical validity for Allix5.

    Investigational mammography-based AI risk prediction

    The service is considered investigational.

    Investigational use: Mammography-based AI risk prediction software is used for individuals undergoing bilateral screening mammography to estimate their 5-year risk of developing breast cancer.

    The policy classifies this use as investigational.

    For Clairity Allix5, synthetic 2D images, digital breast tomosynthesis-derived 2D images, and images acquired from equipment manufactured by companies other than Hologic are outside the validated acquisition profile and should not be used for clinical risk prediction.

    Mirai has not been approved or cleared by the U.S. Food and Drug Administration and is designated for research purposes only until FDA authorization.

    Eligible Clinical Use Contexts

    Mammography-based AI software for 5-year breast cancer risk prediction

    This indication describes the clinical use addressed by the policy.

    Bilateral screening mammography risk prediction: The individual is undergoing bilateral screening mammography, has no known breast cancer at presentation, and the software is used to estimate 5-year breast cancer risk.5-year risk

    This use is considered investigational under the policy.

    Five-year breast cancer risk prediction from routine bilateral screening mammography

    The routine bilateral screening mammogram must provide the standard 2D views used by the risk-prediction software.

    Input requirements: The individual is undergoing routine bilateral screening mammography and the software receives the four standard 2D screening views: RCC, LCC, RMLO, and LMLO.4 standard 2D views

    Procedure and Risk-Threshold Coding Information

    Procedure InvestigationalCPTExperimental
    19499Unlisted procedure, breast
    Increased-risk age threshold
    Age threshold≥35 years
    Increased-risk risk threshold
    Five-year invasive breast cancer risk≥1.7%

    Documentation and Utilization Guidance

    Documentation Required

    Document Validated Mammography Acquisition

    For Clairity Allix5, document that the study was directly acquired as a bilateral 2D screening mammogram using a validated acquisition platform and format.

    • Directly acquired bilateral 2D screening mammograms
    • Hologic Selenia Dimensions or Lorad Selenia mammography system
    Documentation Required

    Document Clinical Use Context

    Document that the service was performed in the context of bilateral screening mammography and, when applicable, that the individual had no known breast cancer at presentation.

    • Bilateral screening mammography
    • No known breast cancer at presentation, when applicable

    Policy and Technology Background

    Mammography-based AI risk prediction software analyzes images from bilateral screening mammography to estimate the likelihood that an individual will develop or be diagnosed with breast cancer within 5 years. The resulting estimate may support discussions about breast cancer screening and prevention; however, this policy considers the technology investigational because evidence is insufficient to demonstrate that its use improves health outcomes.

    Terms and Abbreviations

    Artificial intelligence (AI)
    DefinitionA type of computer technology that analyzes large amounts of information and identifies patterns; in this policy, AI software analyzes breast imaging studies to estimate future breast cancer risk.
    Bilateral screening mammography
    DefinitionAn X-ray examination of both breasts performed to look for signs of breast cancer before symptoms develop; in this policy, the images are used as input for a 5-year breast cancer risk prediction.
    Mammography-based AI risk prediction software
    DefinitionSoftware that uses images from bilateral screening mammography to estimate an individual's chance of developing or being diagnosed with breast cancer during the subsequent five years.

    Risk Reassessment Frequency

    Mammography-based AI risk prediction
    Reassessment frequencyPeriodic reassessment is recommended only when risk factors change.

    Excluded Imaging Inputs and Uses

    The following are not covered as inputs for mammography-based AI clinical risk prediction: synthetic 2D images, digital breast tomosynthesis-derived 2D images, and images acquired from manufacturers other than those included in the validated acquisition profile for the specific software. For Clairity Allix5, validated acquisition is limited to directly acquired bilateral 2D screening mammograms from Hologic Selenia Dimensions or Lorad Selenia systems.

    Policy Summary
    PayerPremera Blue Cross of Washington
    PolicyMammography-Based AI Breast Cancer Risk Prediction
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateFebruary 5, 2027
    Next Review DateN/A
    Key ActionDocument that the input consists of directly acquired bilateral 2D screening mammograms from a validated platform and format.
    SourceLink
    On This Page
    Investigational Status and Evidence RequirementsEligible Clinical Use ContextsProcedure and Risk-Threshold Coding InformationDocumentation and Utilization GuidancePolicy and Technology BackgroundTerms and AbbreviationsRisk Reassessment FrequencyExcluded Imaging Inputs and Uses

    For Clairity Allix5 and Mirai, the source images must be acquired from Hologic Selenia Dimensions or Lorad Selenia mammography systems. Synthetic 2D images and images from non-Hologic acquisition platforms are not supported.

    Mammography-based AI estimation of 5-year breast cancer risk during bilateral screening mammography

    This indication applies to risk estimation performed during bilateral screening mammography.

    Bilateral screening mammography with AI risk prediction: The individual is undergoing bilateral screening mammography and mammography-based AI risk prediction software is used to estimate 5-year breast cancer risk.5-year risk

    This use is considered investigational.

    Documentation Required

    Document Bilateral Screening Views and Platform

    Document routine bilateral screening mammography using all four standard 2D screening views and identify the acquisition platform.

    • Right craniocaudal (RCC) view
    • Left craniocaudal (LCC) view
    • Right mediolateral oblique (RMLO) view
    • Left mediolateral oblique (LMLO) view
    • Acquired from Hologic Selenia Dimensions or Lorad Selenia mammography systems
    Denial Risk

    Investigational AI Risk Prediction

    Mammography-based AI risk prediction software used with bilateral screening mammography to estimate an individual's five-year risk of developing breast cancer is considered investigational (unproven).

    • The evidence is insufficient to show that this service is effective.
    Denial Risk

    Do Not Use Unvalidated Imaging Inputs

    Do not use imaging inputs outside Clairity Allix5's validated acquisition profile for clinical risk prediction.

    • Do not use synthetic 2D images
    • Do not use digital breast tomosynthesis-derived 2D images
    • Do not use images acquired from other manufacturers' equipment
    Billing Rule

    Use No More Than One Mammography-Based AI Model

    Do not use more than one mammography-based AI risk prediction model to estimate five-year breast cancer risk. A clinical risk prediction model may be paired with a mammography-based AI model in subgroups where AI performance is less well established; this limitation does not apply to clinical or comprehensive family-history-based risk assessment or genetic testing for hereditary breast cancer risk.

    • Use of multiple mammography-based AI risk prediction models is not indicated.
    • Periodic reassessment is recommended only when risk factors change.
    Denial Risk

    Insufficient Evidence of Clinical Benefit

    Evidence is insufficient to establish that mammography-based AI risk prediction improves net health outcomes. Coverage or authorization may be challenged on the basis that clinical benefit has not been demonstrated.

    • No direct evidence demonstrates improved health outcomes.
    • Indirect evidence is insufficient to establish clinical validity or clinical utility.
    Denial Risk

    Mirai Lacks FDA Authorization

    Mirai has not been approved or cleared by the U.S. Food and Drug Administration and is for research purposes only until authorized by the FDA.

    • Do not treat Mirai as an FDA-authorized or FDA-cleared clinical device.
    Denial Risk

    Investigational AI Risk Prediction During Screening

    Use of mammography-based AI risk prediction during bilateral screening mammography to estimate five-year breast cancer risk is investigational, including use of the Mirai algorithm.

    • The policy considers this use investigational for individuals undergoing bilateral screening mammography.
    • Mirai's lack of FDA authorization further precludes conclusions regarding its clinical utility.
    Increased-risk threshold
    Definition and calculation basisA 5-year invasive breast cancer risk of at least 1.7%, calculated using the Gail Model or an imaging-based risk assessment model, that is used to identify individuals for an increased-risk screening and follow-up pathway.
    AFAB
    AFABAssigned female at birth
    AH
    AHAtypical hyperplasia
    AMAB
    AMABAssigned male at birth
    BI-RADS
    BI-RADSBreast imaging reporting and data system
    BOADICEA
    BOADICEAThe breast and ovarian analysis of disease incidence and carrier estimation algorithm
    DCIS
    DCISDuctal carcinoma in situ
    FNA
    FNAFine-needle aspiration
    LCIS
    LCISLobular carcinoma in situ
    PRS
    PRSPolygenic risk score
    SNP
    SNPSingle nucleotide polymorphism